Navigation Links
Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
Date:12/28/2009

PRINCETON, N.J., Dec. 28 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)). RiVax((TM)) is Soligenix's vaccine to protect against exposure to ricin toxin and is currently being evaluated in Phase 1 human safety and immunogenicity trials, as well as nonhuman primate trials for efficacy.

The article, entitled "A Monoclonal Immunoglobulin G Antibody Directed against an Immunodominant Linear Epitope on the Ricin A Chain Confers Systemic and Mucosal Immunity to Ricin," is the result of collaborative efforts between the Wadsworth Center of the New York State Department of Health (Albany, NY) and Soligenix. The research was funded in large part by several National Institutes of Health (NIH) grants to the Company for the development of RiVax((TM)). The full article (Neal et al., Infection and Immunity, 2010, volume 78: pp. 552-561) is available online at: http://iai.asm.org/cgi/content/abstract/78/1/552.

In this study, the investigators produced and characterized a monoclonal antibody directed against a region ("epitope") of the ricin A chain previously known to be highly immunologically stimulatory ("immunodominant") in humans. The monoclonal antibody was shown to bind the ricin A chain with high affinity, and to be capable of neutralizing ricin toxin in a cell-based killing assay. Moreover, when administered passively to mice, the neutralizing antibod
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
2. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... in Santa Ana, California is a ... market for which is estimated at $22 billion in the ... includes the use of FDA-approved Naltrexone in a specially compounded ... (excluding Australia and New ...
(Date:3/27/2015)... -- Levi & Korsinsky announces it has commenced an ... concerning possible violations of federal securities laws. The investigation ... with its study of the drug OHR-102. To obtain ... Joseph E. Levi, Esq. either via email ... 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky ...
(Date:3/27/2015)... - Russell Williams , President of ... 2015-2016 Quebec Budget, noting the fiscal discipline and the ... However, the association is concerned about the decline of ... intent to strive for a balanced budget this year, ... Quebec,s economic development is encouraging," said Mr. ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, November 2, 2011, after the close of U.S.-based financial ... a conference call to review the results beginning at 5:00 ... The press release and a live audio-only Webcast of ...
... Oct. 26, 2011 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... with the U.S. Food and Drug Administration (FDA) to ... ANX-514 (docetaxel for injectable emulsion), a detergent-free reformulation of ... study (Study 514-02) with a primary objective of comparing ...
Cached Medicine Technology:Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets 2ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 2ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 3ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514 4
(Date:3/29/2015)... 2015 Youth Villages will participate in ... to assess the feasibility of implementing a Pay for ... problems and their families. , Third Sector Capital Partners ... will be provided technical assistance throughout 2015 toward a ... other national awardees chosen by Third Sector. The organization’s ...
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... W. Brickner, “and as we learn more about the ... , In March Homeostasis: Publius’ Go Endo-Cannabinoid Update ... homeostatic health, or endo-healing, is celebrated. Publius, of The ... four 2015 National Institutes of Health (PubMed) cannabinoid system ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... clinic that offers urgent care in Manhattan, recently commemorated ... urgent care facility in Manhattan. In addition to 24-hour ... to ER facilities. , At this time, Emergency ... treatments for abdominal pain, asthma, chest pain, eye injuries, ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:March Homeostasis: Publius’ Go Endo-Cannabinoid Update ~ New on the Bryan William Brickner Blog 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2
... ... provides a central source for gaining insight, sharing opinions and finding resources on hospital ... ... launched an online community for hospitals: www.theQsphere.com . TheQsphere.com provides a central source ...
... Ky., June 15 VirtualHealth Technologies, Inc. (OTC Bulletin ... agreement to partner with Silk Information Systems, Inc. (SILK) ... and Billing solutions with no cost of entry to ... subsidiary Medical Office Software (MOS). , ...
... St. Louis, MO, June 15, 2009 Calcium and dairy ... of chronic disease. Because peak bone mass is not achieved ... for young adults to consume adequate amounts of calcium, protein ... and prevent osteoporosis later in life. In a study in ...
... Used to Develop DNA-Guided Decision Support for Statin Prescription ... biomedical company advancing DNA-guided medicine and personalized healthcare, announced ... Atherosclerosis, a meeting held triennially by the International Atherosclerosis ... present " Physiogenomic Contours of Statin Safety ...
... Amira Pharmaceuticals, Inc. announced today that it will present ... June 30, 2009 at the Federation of American Societies ... Arizona. , , The LPA1 receptor is part ... is associated with cell to cell communication. In recent ...
... Despite the severe economic downturn, assisted living remains enormously ... in a new national survey. , , The 2009 ... of the industry conducted by the leading senior living associations, ... a slight decrease from the 2006 survey when the economy ...
Cached Medicine News:Health News:New Online Community Answers Hospital Questions about ARRA QHR Announces Launch of theQsphere.com 2Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 2Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 3Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 4Health News:VirtualHealth and Silk Partner to Provide Physicians with Revenue Recovery Solutions 5Health News:Young adults not drinking enough milk 2Health News:Genomas Presents Drug-Specific Genetic Determinants of Statin Safety and Efficacy at the XV International Symposium on Atherosclerosis 2Health News:Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference 2Health News:Safety and Quality Contribute to Popularity of Assisted Living 2
... strong heritage in patient monitoring, IntelliVue has ... measurements menu; built-in clinical support tools such ... and arrhythmia analysis; and many other powerful ... and operates on a networked platform that ...
... is designed to match the pace and ... environments. Built on Philips strong heritage in ... independent displays has highly flexible screen configuration; ... support tools such as Event Surveillance, EASI ...
... Nightingale Monitoring System™ expands hospital-grade monitoring capabilities ... subacute care and disease state management. ... to encompass a full range of clinical ... inside the hospital, to periodic monitoring of ...
... Narkotron II is a comprehensive vital sign monitor. , ... quality, affordable products for efficiency in patient care., ... 2 - Temp - Multi-gas Sensor (HAL, ... )., ,Optional Functions: ,5-Lead ECG - FiO 2 ...
Medicine Products: